Clinical Trial Update: Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial (MOSAIC) is evaluating the combination of midostaurin and gemtuzumab ozogamicin as part of first-line therapy for acute myeloid leukemia and i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Mylotarg (gemtuzumab ozogamicin)
• Rydapt (midostaurin)

Snippet

Sponsor: Technische Universität Dresden | Conditions: Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: RECRUITING